Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ARROWHEAD PHARMACEUTICALS, INC.ARWR · Entity 3472 | Director | January 10, 2023 | January 12, 2023 |
| Kronos Bio, Inc.KRON · Entity 78257 | Director | June 22, 2023 | June 26, 2023 |
| Vir Biotechnology, Inc.VIR · Entity 4522 | Director · President and CEO | April 29, 2026 | April 30, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ARROWHEAD PHARMACEUTICALS, INC.
Report date January 10, 2023 · Filed January 12, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 31,267 |
Reported balance
After 2023-01-10 transaction · row 1
1 source rowRow 1 · 2023-01-10 · Grant · Acquired 7,867 · Balance 31,267 F1: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date. |
| Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $33.03 · Expires 2033-01-10 | Direct | 4,593 |
Reported balance
After 2023-01-10 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-01-10 · Grant · Acquired 4,593 · Balance 4,593 F2: Represents options, which will vest in one installment on the first anniversary of the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date.
F2: Represents options, which will vest in one installment on the first anniversary of the grant date.
Kronos Bio, Inc.
Report date June 22, 2023 · Filed June 26, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.48 · Expires 2033-06-21 | Direct | 34,000 |
Reported balance
After 2023-06-22 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-06-22 · Grant · Acquired 34,000 · Balance 34,000 F1: The shares subject to the option will vest upon the earlier of (a) the one-year anniversary of the date of grant and (b) the date of the Issuer's next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: The shares subject to the option will vest upon the earlier of (a) the one-year anniversary of the date of grant and (b) the date of the Issuer's next annual meeting of stockholders.
Vir Biotechnology, Inc.
Report date April 29, 2026 · Filed April 30, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 714,613 |
Reported balance
After 2026-04-29 transaction · row 1
1 source rowRow 1 · 2026-04-29 · Other · Disposed 233,532 · Balance 714,613 F1: Transfer without consideration for tax and estate planning purposes. |
| Common StockSEC Table I · non-derivative | IndirectSee Footnote | 286,650 |
Reported balance
After 2026-04-29 transaction · row 2
Account identity is unresolved; indirect or unspecified ownership is not merged.
1 source rowRow 2 · 2026-04-29 · Other · Acquired 233,532 · Balance 286,650 F1: Transfer without consideration for tax and estate planning purposes. F2: The shares are held in the name of the Ureel-De Backer Family Trust, of which the Reporting Person and her spouse are Trustees. |
Filing footnotes · ownership attribution and instrument terms
F1: Transfer without consideration for tax and estate planning purposes.
F2: The shares are held in the name of the Ureel-De Backer Family Trust, of which the Reporting Person and her spouse are Trustees.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 29, 2026 Filed Apr 30, 2026 21:43 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 233,532 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-029041 · wk-form4_1777585398.xml · nonDerivative · entry 2 De Backer Marianne · CIK 0001797819 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 286,650 F1 · kind: Transfer without consideration for tax and estate planning purposes. F2 · ownership.nature: The shares are held in the name of the Ureel-De Backer Family Trust, of which the Reporting Person and her spouse are Trustees. Read SEC document |
| April 29, 2026 Filed Apr 30, 2026 21:43 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 233,532 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-029041 · wk-form4_1777585398.xml · nonDerivative · entry 1 De Backer Marianne · CIK 0001797819 · Director · President and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 714,613 F1 · kind: Transfer without consideration for tax and estate planning purposes. Read SEC document |
| April 06, 2026 Filed Apr 7, 2026 20:50 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 72,559 | $9.16 | $664,350.20 |
DisclosureSEC source: 0001628280-26-024098 · wk-form4_1775595054.xml · nonDerivative · entry 1 De Backer Marianne · CIK 0001797819 · Director · President and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 948,145 F1 · kind: Represents an automatic and mandatory sale of shares under a Rule 10b5-1 arrangement to satisfy the Issuer's tax withholding obligations in connection with the vesting of restricted stock units. The sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 21:54 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 14,762 | $9.53 | $140,720.24 |
DisclosureSEC source: 0001628280-26-012390 · wk-form4_1772142870.xml · nonDerivative · entry 1 De Backer Marianne · CIK 0001797819 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,020,704 F1 · kind: Represents an automatic and mandatory sale of shares under a Rule 10b5-1 arrangement to satisfy the Issuer's tax withholding obligations in connection with the vesting of restricted stock units. The sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| February 23, 2026 Filed Feb 25, 2026 00:09 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 19,039 | $7.45 | $141,893.86 |
DisclosureSEC source: 0001628280-26-011327 · wk-form4_1771978165.xml · nonDerivative · entry 2 De Backer Marianne · CIK 0001797819 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,035,466 F2 · kind: Represents an automatic and mandatory sale of shares under a Rule 10b5-1 arrangement to satisfy the Issuer's tax withholding obligations in connection with the vesting of RSUs. The sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| February 22, 2026 Filed Feb 25, 2026 00:09 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantStock Option (Right to Buy) · Derivative | 570,000 | $0.00 Strike: $7.56 | $0.00 |
DisclosureSEC source: 0001628280-26-011327 · wk-form4_1771978165.xml · derivative · entry 4 De Backer Marianne · CIK 0001797819 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 570,000 Underlying: Common Stock · 570,000 shares Expires 2036-02-21 F4 · derivative.exercise_date: 25% of the shares subject to the stock option will vest and become exercisable on February 22, 2027, and the remaining shares will vest in 36 equal monthly installments thereafter. Read SEC document |
| February 22, 2026 Filed Feb 25, 2026 00:09 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantCommon Stock | 285,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-26-011327 · wk-form4_1771978165.xml · nonDerivative · entry 1 De Backer Marianne · CIK 0001797819 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,054,505 F1 · kind: Acquisition of restricted stock units (RSUs) pursuant to the Issuer's Equity Incentive Plan. Read SEC document |
| April 03, 2025 Filed Apr 4, 2025 20:23 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 79,712 | $5.95 | $474,238.57 |
DisclosureSEC source: 0001628280-25-016800 · wk-form4_1743798213.xml · nonDerivative · entry 1 De Backer Marianne · CIK 0001797819 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 769,505 F1 · kind: Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units. Read SEC document |
| February 24, 2025 Filed Feb 25, 2025 20:36 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 16,122 | $9.45 | $152,407.71 |
DisclosureSEC source: 0001628280-25-007693 · wk-form4_1740515751.xml · nonDerivative · entry 2 De Backer Marianne · CIK 0001797819 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 849,217 F2 · kind: Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units. Read SEC document |
| February 22, 2025 Filed Feb 25, 2025 20:36 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantStock Option (Right to Buy) · Derivative | 480,000 | $0.00 Strike: $9.57 | $0.00 |
DisclosureSEC source: 0001628280-25-007693 · wk-form4_1740515751.xml · derivative · entry 4 De Backer Marianne · CIK 0001797819 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 480,000 Underlying: Common Stock · 480,000 shares Expires 2035-02-21 F4 · derivative.exercise_date: 25% of the shares subject to the stock option vest and become exercisable on February 22, 2026, and the remaining shares vest in 36 equal monthly installments thereafter. Read SEC document |
| February 22, 2025 Filed Feb 25, 2025 20:36 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantCommon Stock | 240,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-25-007693 · wk-form4_1740515751.xml · nonDerivative · entry 1 De Backer Marianne · CIK 0001797819 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 865,339 F1 · kind: Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan. Read SEC document |
| June 12, 2024 Filed Jun 12, 2024 20:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 53,118 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-027797 · wk-form4_1718222423.xml · nonDerivative · entry 2 De Backer Marianne · CIK 0001797819 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Indirect · See Footnote Disclosed balance after: 53,118 F1 · kind: Transfer without consideration for tax planning purposes. F2 · ownership.nature: The shares are held in the name of the Ureel-De Backer Family Trust, of which the reporting person and her spouse are Trustees. Read SEC document |
| June 12, 2024 Filed Jun 12, 2024 20:00 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | OtherCommon Stock | 53,118 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-027797 · wk-form4_1718222423.xml · nonDerivative · entry 1 De Backer Marianne · CIK 0001797819 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 625,339 F1 · kind: Transfer without consideration for tax planning purposes. Read SEC document |
| April 03, 2024 Filed Apr 4, 2024 20:14 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | SaleCommon Stock | 72,995 | $9.46 | $690,364.81 |
DisclosureSEC source: 0001628280-24-014878 · wk-form4_1712261678.xml · nonDerivative · entry 1 De Backer Marianne · CIK 0001797819 · Director · Chief Executive Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 678,457 F1 · kind: Represents the automatic sale of shares to cover the Issuer's tax withholding and remittance obligation in connection with the vesting of restricted stock units. Read SEC document |
| February 22, 2024 Filed Feb 27, 2024 00:32 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantStock Option (Right to Buy) · Derivative | 350,000 | $0.00 Strike: $10.11 | $0.00 |
DisclosureSEC source: 0001628280-24-006984 · wk-form4_1708993962.xml · derivative · entry 2 De Backer Marianne · CIK 0001797819 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 350,000 Underlying: Common Stock · 350,000 shares Expires 2034-02-21 F2 · derivative.exercise_date: 25% of the shares subject to the stock option vest and become exercisable on February 22, 2025, and the remainder vest in 36 equal monthly installments thereafter. Read SEC document |
| February 22, 2024 Filed Feb 27, 2024 00:32 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantCommon Stock | 175,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001628280-24-006984 · wk-form4_1708993962.xml · nonDerivative · entry 1 De Backer Marianne · CIK 0001797819 · Director · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 751,452 F1 · kind: Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan. Read SEC document |
| June 22, 2023 Filed Jun 26, 2023 16:11 UTC | Kronos Bio, Inc. KRON · Entity 78257 | GrantStock Option (Right to Buy) · Derivative | 34,000 | $0.00 Strike: $1.48 | $0.00 |
DisclosureSEC source: 0001209191-23-039688 · doc4.xml · derivative · entry 1 De Backer Marianne · CIK 0001797819 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,000 Underlying: Common Stock · 34,000 shares Expires 2033-06-21 F1 · derivative.exercise_date: The shares subject to the option will vest upon the earlier of (a) the one-year anniversary of the date of grant and (b) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| April 03, 2023 Filed Apr 4, 2023 20:53 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantStock Option (Right to Buy) · Derivative | 1,152,904 | $0.00 Strike: $23.28 | $0.00 |
DisclosureSEC source: 0001209191-23-022777 · doc4.xml · derivative · entry 2 De Backer Marianne · CIK 0001797819 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,152,904 Underlying: Common Stock · 1,152,904 shares Expires 2033-04-02 F2 · derivative.exercise_date: 25% of the shares subject to the stock option vest and become exercisable on April 3, 2024, and the remainder vest in 36 equal monthly installments thereafter. Read SEC document |
| April 03, 2023 Filed Apr 4, 2023 20:53 UTC | Vir Biotechnology, Inc. VIR · Entity 4522 | GrantCommon Stock | 576,452 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-022777 · doc4.xml · nonDerivative · entry 1 De Backer Marianne · CIK 0001797819 · Chief Executive Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 576,452 F1 · kind: Acquisition of restricted stock units pursuant to the Issuer's Equity Incentive Plan. Read SEC document |
| January 10, 2023 Filed Jan 12, 2023 01:38 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock · Derivative | 4,593 | $0.00 Strike: $33.03 | $0.00 |
DisclosureSEC source: 0001209191-23-003081 · doc4.xml · derivative · entry 2 De Backer Marianne · CIK 0001797819 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,593 Underlying: Common Stock · 4,593 shares Expires 2033-01-10 F2 · shares: Represents options, which will vest in one installment on the first anniversary of the grant date. Read SEC document |
| January 10, 2023 Filed Jan 12, 2023 01:38 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock | 7,867 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-003081 · doc4.xml · nonDerivative · entry 1 De Backer Marianne · CIK 0001797819 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,267 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date. Read SEC document |
| June 22, 2022 Filed Jun 29, 2022 16:14 UTC | Kronos Bio, Inc. KRON · Entity 78257 | GrantStock Option (Right to Buy) · Derivative | 17,000 | $0.00 Strike: $3.53 | $0.00 |
DisclosureSEC source: 0001209191-22-039788 · doc4.xml · derivative · entry 2 De Backer Marianne · CIK 0001797819 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2032-06-21 F1 · derivative.exercise_date: The shares subject to the option will vest upon the earlier of (a) the one-year anniversary of the date of grant and (b) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| June 22, 2022 Filed Jun 29, 2022 16:14 UTC | Kronos Bio, Inc. KRON · Entity 78257 | GrantCommon Stock | 11,333 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-039788 · doc4.xml · nonDerivative · entry 1 De Backer Marianne · CIK 0001797819 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,083 Read SEC document |
| January 07, 2022 Filed Jan 8, 2022 01:07 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock | 6,400 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-002586 · doc4.xml · nonDerivative · entry 1 De Backer Marianne · CIK 0001797819 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,400 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 02:31 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 272 | $66.25 | $18,020.00 |
DisclosureSEC source: 0001209191-22-001323 · doc4.xml · nonDerivative · entry 3 De Backer Marianne · CIK 0001797819 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 F1 · shares: The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 02:31 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 1,984 | $65.01 | $128,979.84 |
DisclosureSEC source: 0001209191-22-001323 · doc4.xml · nonDerivative · entry 2 De Backer Marianne · CIK 0001797819 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,272 F1 · shares: The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.73 to $65.57, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| January 03, 2022 Filed Jan 5, 2022 02:31 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 2,244 | $64.25 | $144,177.00 |
DisclosureSEC source: 0001209191-22-001323 · doc4.xml · nonDerivative · entry 1 De Backer Marianne · CIK 0001797819 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,256 F1 · shares: The sale was made to generate proceeds to cover the tax liability incident to the vesting of restricted stock units. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $63.72 to $64.69, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. Read SEC document |
| December 01, 2021 Filed Dec 2, 2021 17:12 UTC | Kronos Bio, Inc. KRON · Entity 78257 | PurchaseCommon Stock | 1,150 | $11.57 | $13,305.50 |
DisclosureSEC source: 0001209191-21-067658 · doc4.xml · nonDerivative · entry 1 De Backer Marianne · CIK 0001797819 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,750 F1 · price: The weighted average purchase price for the transaction reported was $11.57, and the range of prices were between $11.38 and $11.79. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document |
| August 20, 2021 Filed Aug 24, 2021 19:24 UTC | Kronos Bio, Inc. KRON · Entity 78257 | PurchaseCommon Stock | 500 | $19.63 | $9,815.00 |
DisclosureSEC source: 0001209191-21-053243 · doc4.xml · nonDerivative · entry 2 De Backer Marianne · CIK 0001797819 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,600 Read SEC document |
| August 20, 2021 Filed Aug 24, 2021 19:24 UTC | Kronos Bio, Inc. KRON · Entity 78257 | PurchaseCommon Stock | 500 | $19.50 | $9,750.00 |
DisclosureSEC source: 0001209191-21-053243 · doc4.xml · nonDerivative · entry 1 De Backer Marianne · CIK 0001797819 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,100 Read SEC document |
| June 24, 2021 Filed Jun 25, 2021 22:59 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | SaleCommon Stock | 5,000 | $89.85 | $449,250.00 |
DisclosureSEC source: 0001209191-21-043406 · doc4.xml · nonDerivative · entry 1 De Backer Marianne · CIK 0001797819 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,500 F1 · price: The price reported on Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $89.76 to $90.03, inclusive. The reporting person undertakes to provide to Arrowhead Pharmaceuticals, Inc., any security holder of Arrowhead Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote of this Form 4. F2 · balance_after: Includes previously reported shares of common stock underlying Restricted Stock Units granted to the Reporting person which are subject to certain vesting conditions. Read SEC document |
| June 22, 2021 Filed Jun 23, 2021 21:21 UTC | Kronos Bio, Inc. KRON · Entity 78257 | GrantStock Option (Right to Buy) · Derivative | 8,583 | $0.00 Strike: $24.18 | $0.00 |
DisclosureSEC source: 0001209191-21-042890 · doc4.xml · derivative · entry 1 De Backer Marianne · CIK 0001797819 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,583 Underlying: Common Stock · 8,583 shares Expires 2031-06-21 F1 · derivative.exercise_date: The shares subject to the option will vest upon the earlier of (a) the one-year anniversary of the date of grant and (b) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| May 28, 2021 Filed Jun 1, 2021 16:08 UTC | Kronos Bio, Inc. KRON · Entity 78257 | PurchaseCommon Stock | 600 | $25.01 | $15,006.00 |
DisclosureSEC source: 0001209191-21-036799 · doc4.xml · nonDerivative · entry 1 De Backer Marianne · CIK 0001797819 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 600 F1 · shares: The weighted average purchase price for the transaction reported was $25.01, and the range of prices were between $24.52 and $25.32. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. F1 · price: The weighted average purchase price for the transaction reported was $25.01, and the range of prices were between $24.52 and $25.32. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares purchased at each separate price will be provided. Read SEC document |
| January 25, 2021 Filed Jan 27, 2021 17:03 UTC | Kronos Bio, Inc. KRON · Entity 78257 | GrantStock Option (right to buy) · Derivative | 41,200 | $0.00 Strike: $31.70 | $0.00 |
DisclosureSEC source: 0001209191-21-005710 · doc4.xml · derivative · entry 1 De Backer Marianne · CIK 0001797819 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,200 Underlying: Common Stock · 41,200 shares Expires not disclosed F1 · derivative.exercise_date: The shares subject to the option vest in annual installments over 3 years following the date of grant. F1 · derivative.expiration_date: The shares subject to the option vest in annual installments over 3 years following the date of grant. Read SEC document |
| January 01, 2021 Filed Jan 5, 2021 23:22 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock | 9,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-001558 · doc4.xml · nonDerivative · entry 1 De Backer Marianne · CIK 0001797819 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 26,500 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date. Read SEC document |
| October 08, 2020 Filed Oct 26, 2020 22:02 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | PurchaseCommon Stock | 500 | $50.00 | $25,000.00 |
DisclosureSEC source: 0001209191-20-055851 · doc4.xml · nonDerivative · entry 2 De Backer Marianne · CIK 0001797819 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,500 Read SEC document |
| October 08, 2020 Filed Oct 26, 2020 22:02 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | PurchaseCommon Stock | 500 | $50.93 | $25,465.00 |
DisclosureSEC source: 0001209191-20-055851 · doc4.xml · nonDerivative · entry 1 De Backer Marianne · CIK 0001797819 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 Read SEC document |
| June 15, 2020 Filed Jun 24, 2020 22:10 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | PurchaseCommon Stock | 500 | $31.33 | $15,665.00 |
DisclosureSEC source: 0001209191-20-038767 · doc4.xml · nonDerivative · entry 8 De Backer Marianne · CIK 0001797819 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,500 Read SEC document |
| April 15, 2020 Filed Jun 24, 2020 22:10 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | PurchaseCommon Stock | 500 | $35.40 | $17,700.00 |
DisclosureSEC source: 0001209191-20-038767 · doc4.xml · nonDerivative · entry 7 De Backer Marianne · CIK 0001797819 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 Read SEC document |
| March 16, 2020 Filed Jun 24, 2020 22:10 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | PurchaseCommon Stock | 500 | $23.94 | $11,970.00 |
DisclosureSEC source: 0001209191-20-038767 · doc4.xml · nonDerivative · entry 6 De Backer Marianne · CIK 0001797819 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,500 Read SEC document |
| March 12, 2020 Filed Jun 24, 2020 22:10 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | PurchaseCommon Stock | 500 | $24.80 | $12,400.00 |
DisclosureSEC source: 0001209191-20-038767 · doc4.xml · nonDerivative · entry 5 De Backer Marianne · CIK 0001797819 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Read SEC document |
| March 11, 2020 Filed Jun 24, 2020 22:10 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | PurchaseCommon Stock | 500 | $28.60 | $14,300.00 |
DisclosureSEC source: 0001209191-20-038767 · doc4.xml · nonDerivative · entry 4 De Backer Marianne · CIK 0001797819 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,500 Read SEC document |
| February 28, 2020 Filed Jun 24, 2020 22:10 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | PurchaseCommon Stock | 500 | $34.39 | $17,195.00 |
DisclosureSEC source: 0001209191-20-038767 · doc4.xml · nonDerivative · entry 3 De Backer Marianne · CIK 0001797819 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 Read SEC document |
| February 27, 2020 Filed Jun 24, 2020 22:10 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | PurchaseCommon Stock | 500 | $35.07 | $17,535.00 |
DisclosureSEC source: 0001209191-20-038767 · doc4.xml · nonDerivative · entry 2 De Backer Marianne · CIK 0001797819 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,500 Read SEC document |
| January 13, 2020 Filed Jun 24, 2020 22:10 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | PurchaseCommon Stock | 500 | $54.95 | $27,475.00 |
DisclosureSEC source: 0001209191-20-038767 · doc4.xml · nonDerivative · entry 1 De Backer Marianne · CIK 0001797819 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,000 Read SEC document |
| January 01, 2020 Filed Jan 3, 2020 23:10 UTC | ARROWHEAD PHARMACEUTICALS, INC. ARWR · Entity 3472 | GrantCommon Stock | 7,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-001372 · doc4.xml · nonDerivative · entry 1 De Backer Marianne · CIK 0001797819 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,500 F1 · shares: Represents shares underlying a restricted stock unit, which shares will vest in one installment on the first anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.